Vermillion's (VRML) ASPiRA LABs Enters Major Agreement with CareFirst BCBS

September 29, 2016 9:10 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

ASPiRA LABs, a Vermillion company (Nasdaq: VRML) announced a major contract agreement with CareFirst BlueCross BlueShield for their U.S. FDA cleared ovarian cancer risk assessment test, OVA1. CareFirst serves over three million patients throughout Maryland and Washington, D.C., and Virginia and the area has the greatest population density in the US.

"We are pleased to announce CareFirst BlueCross BlueShield contract agreement for OVA1," said Valerie Palmieri, President and CEO of Vermillion, Inc. "This is our fourth recent announcement of new managed care contracts as we continue to expand our reach in our key strategic market areas."

"The mortality rate of ovarian cancer has not changed in 40 years, even following the introduction of CA125. Given the FDA safety statement on Ovarian Cancer Screening, expanding coverage and increasing access to OVA1 for women with a pelvic mass is vital to ensuring optimal care for patients nationwide. Days and weeks matter with Ovarian Cancer. Treatment for two thirds of women with ovarian cancer does not follow the appropriate carepathway. OVA1 can change this from this onset and give piece of mind for patients with OR without disease."

Links to multiple clinical studies showing OVA1's strong performance over CA125 for earlier and improved detection can be found on our website: http://vermillion.com/providers/ova-1/clinical-validation-studies/.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News

Add Your Comment